Latest capsid deal gives a lifeline to Sangamo: Deals Report

With cash running low, Sangamo forged another deal around its capsid platform that will extend the long-running biotech’s runway, adding Lilly to its list of partners for its CNS-penetrant delivery platform.

Late Thursday, Sangamo Therapeutics Inc. (NASDAQ:SGMO) said Eli Lilly and Co. (NYSE:LLY) will pay $18 million up front to use its STAC-BBB capsids in therapeutics against up to five undisclosed targets. The arrangement makes Sangamo eligible for $1.4 billion in fees and milestones, plus royalties...